Table 1 Characteristics of the development and validation cohorts
Variable | Development cohort (n = 85) | Validation cohort (n = 38) | P-value |
|---|---|---|---|
Male gender, n (%) | 51 (60.00%) | 27 (71.05%) | 0.312 |
Age (years), mean ± SD | 72.12 ± 12.96 | 71.76 ± 13.07 | 0.889 |
Baseline NIHSS, median (IQR) | 18 (14.50–23) | 20 (13.75–27) | 0.438 |
Hypertension, n (%) | 56 (65.88%) | 25 (65.79%) | 0.992 |
Diabetes mellitus, n (%) | 20 (23.53%) | 3 (7.89%) | 0.046 |
Hyperlipidemia, n (%) | 15 (17.65%) | 12 (31.58%) | 0.101 |
Atrial fibrillation, n (%) | 40 (47.06%) | 21 (55.26%) | 0.439 |
Smoking, n (%) | 27 (31.76%) | 15 (39.47%) | 0.418 |
Alcohol abuse, n (%) | 16 (18.82%) | 10 (26.32%) | 0.350 |
ASPECTS on CT, median (IQR) | 7 (5–9.50) | 7 (3–9) | 0.520 |
HVS of MCA, n (%) | 43 (50.59%) | 24 (63.16%) | 0.241 |
Collateral score, median (IQR) | 1 (1–1) | 1 (1–1) | 0.297 |
Right-side MCA occlusion in the M1 segment, n (%) | 41 (48.24%) | 23 (60.53%) | 0.244 |
ICA occlusion, n (%) | 33 (38.82%) | 18 (47.37%) | 0.430 |